ClearPoint recruits first patient in laser therapy study to treat Glioblastoma

California, US-based ClearPoint Neuro has recruited the first patient in a clinical trial which will use ClearPoint’s Prism Neuro Laser Therapy System.

The clinical trial, conducted at Skåne University Hospital, Sweden, has been called the Safety and Feasibility of MR-Guided Laser Thermal Ablation of Brain Lesions. It is a single-arm clinical trial which will evaluate the safety and feasibility of the minimally-invasive MR-guided laser therapy system to ablate tumours in up to five Glioblastoma patients.

ClearPoint Neuro president and CEO Joe Burnett said, “We are proud to support SUS Lund and CLS on this pilot study using the innovative laser therapy system to treat glioblastoma lesions. The ClearPoint Neuro Navigation System offers an efficient one-room solution that helps neurosurgeons in the United States to accurately place laser fibres and help treat brain tumours, radiation necrosis and epileptic foci in thousands of patients. Expanding brain and spine laser therapy treatment options for patients and neurosurgeons in the EU, and beyond, is a key priority in the years ahead.”

The ClearPoint system is currently being used for standard-of-care treatments, such as tumour biopsy and guiding implantation of deep brain stimulation (DBS) electrodes to target.

Skåne University Hospital neurosurgeon and study principal investigator Peter Siesjö stated, “The clinical trial with minimally invasive laser thermal treatment of patients with recurrent malignant brain tumours, glioblastoma, has now started at Skåne University Hospital and the treatment of the first patient could be carried out as planned. The treatment was performed, for the first time in Sweden, in a magnetic resonance imaging (MRI) suite in order to avoid transporting the patient between surgery and the MRI suite.”

James Spargo